BJH - 2021, issue SPECIAL, january 2021
Prof A. Rijneveld
Acute lymphoblastic leukaemia (ALL) is a rare disease with the highest incidence in childhood and patients older then 60 years. While the long-term outcomes of ALL have improved significantly in the paediatric population and to a lesser extent in young adults, elderly patients still have a very poor prognosis.1,2 In fact, half of all deaths from ALL occur in patients older than 55 years and their 5-year overall survival (OS) rate ranges from 10–20%.3,4 During the 36th general annual meeting of the Belgian Haematology Society Prof. Anita Rijneveld, from the Erasmus Cancer Institute, Rotterdam, the Netherlands, gave an overview of recent advances in the treatment of adults ALL patients.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.